MEDIUM confidence: 100% data completeness, but the composite (64) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $3.0B— | $3.4B+13.7% | $3.7B+8.9% | $4.2B+14.8% | $5.1B+21.2% |
| EPS (dil.) | $4.27— | $1.52-64.4% | $2.65+74.3% | $0.15-94.3% | $6.41+4173.3% |
| Free Cash Flow | $568M— | $892M+56.9% | $449M-49.7% | $249M-44.5% | $1.4B+443.9% |
| Gross Margin | 94.9% | 93.9%-1.0pp | 93.1%-0.8pp | 92.6%-0.5pp | 92.8%+0.1pp |
| Operating Margin | 19.6% | 17.4%-2.2pp | 17.7%+0.3pp | 2.4%-15.3pp | 26.1%+23.7pp |
| Net Margin | 31.8% | 10.0%-21.7pp | 16.2%+6.1pp | 0.8%-15.4pp | 25.0%+24.3pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Avg target $121 (last qtr, 21 analysts) → $130 (last mo, 12) (+6.9%).
Buy-rated share 39% → 41% over ~3 months (+1pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jul 2026 | $2.15 | $3.09 | +43.7% |
| Apr 2026 | $1.34 | $1.81 | +35.1% |
| Feb 2026 | $1.90 | $1.80 | -5.3% |
| Oct 2025 | $1.66 | $2.26 | +36.1% |
| Jul 2025 | $1.39 | $1.57 | +12.9% |
| Apr 2025 | $1.01 | $1.16 | +14.9% |
| Feb 2025 | $1.57 | $1.43 | -8.9% |
| Oct 2024 | $1.12 | $1.07 | -4.5% |
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of -3.7%/yr (revenue basis).
Base free cash flow $684M (avg FY2023–FY2025; latest year $1.4B) · equity value $24.5B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
Net insider -$12.7M over 180 days (0 open-market buys, 18 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Incyte Corporation's QScore of 64 indicates a relatively strong investment profile, driven by high scores in growth and profitability, with revenue growth of 21.2% and ROE near 30%. The stock's value score is somewhat lower, as it trades at a P/E of 14.9, which is not overly expensive but also not particularly cheap. Incyte's momentum score is moderate, reflecting a 52.5% return over the past year, with long-term and short-term scores converging closely, suggesting a consistent investment outlook.